Sage Journals: Discover world-class research

Abstract

Background

Thyroid nodules are stratified through fine-needle aspiration (FNA) and are often categorized using The Bethesda System for Reporting Thyroid Cytopathology, which estimates the risk of malignancy for six cytopathological categories. The atypia of undetermined significance (AUS) and follicular lesion of undetermined significance (FLUS) categories have varying malignancy rates reported in the literature which can range from 6 to 72.9%. Due to this heterogeneity, we assessed the malignancy rate and effectiveness of repeat FNA (rFNA) for AUS/FLUS thyroid cytopathology at our institution.

Methods

Electronic health records of patients with AUS/FLUS thyroid cytopathology on FNA at our center since the implementation of the Bethesda System on May 1, 2014–December 31, 2019 were retrospectively reviewed. Patient demographics, treatment pathway, and pathology results were collected. The treatment pathway of the nodules, the rFNA results, and the malignant histopathology results were reported. Malignancy rates were calculated as an upper and lower limit estimate.

Results

This study described 182 AUS/FLUS thyroid nodules from 177 patients. In total, 24 thyroid nodules were deemed malignant upon histopathology, yielding a final malignancy rate of 13.2–25.3%. All of the malignancies were variants of papillary thyroid carcinoma. The malignancy rate of the nodules which underwent resection without rFNA (21.5%) was lower than the malignancy rate of the nodules which underwent resection after rFNA (43.8%). 45.5% of the rFNA results were re-classified into more definitive categories.

Conclusion

The malignancy rate of AUS/FLUS thyroid cytopathology at our center is in line with the risk of malignancy stated by the 2017 Bethesda System. However, our malignancy rate is lower than some other Canadian centers and approximately half of our rFNAs were re-classified, highlighting the importance of establishing center-specific malignancy and rFNA re-classification rates to guide treatment decisions.

Keywords

Thyroid Bethesda AUS/FLUS Nodule Cytopathology FNA Malignancy rate

Background

The incidence of thyroid cancer continues to increase in Canada and globally [1–4]. Palpation can detect a thyroid nodule in approximately 4% of the general population [1, 5], however ultrasonography can detect nodules in 19–67.6% of the population [1, 6–8]. Thyroid nodules have been reported in up to 64.6% of autopsies [1, 9]. The more frequent usage of advanced medical imaging has resulted in an increased number of thyroid nodules found incidentally, which is hypothesized to partially account for the increased incidence of thyroid cancer [1–4]. Despite this increased incidence, the prognosis of thyroid cancer remains highly favorable, with an overall five-year survival rate of 98% in Canada [2, 3].

Fine-needle aspiration (FNA) is a safe, accurate and cost-effective procedure used to assess thyroid cytopathology and risk of malignancy (ROM) [10]. The Bethesda System for Reporting Thyroid Cytopathology has reduced ambiguity surrounding thyroid FNA results, subsequently decreasing the rate of unnecessary thyroidectomies [11, 12]. The Bethesda System separates thyroid cytopathology into six categories and for each category, the “usual management” and ROM is provided [11]. The management of the atypia of undetermined significance/follicular lesion of undetermined significance (AUS/FLUS) category has been challenging due to its indeterminant nature and heterogeneous reports of malignancy rates [13, 14]. The original Bethesda System states a ROM of ∼ 5–15% for this category, and repeat FNA (rFNA) is recommended [11]. However, various institutions have reported widely ranging malignancy rates from 6 to 72.9% [13–16].

In 2016, histopathology of non-invasive encapsulated follicular variant of papillary thyroid carcinoma (NEFV-PTC) was re-classified as non-invasive follicular thyroid neoplasm with papillary-like nuclear features (NIFTP) to represent its indolent nature [17]. The updated 2017 Bethesda System states a 6–18% ROM for the AUS/FLUS category when NIFTP is not considered malignant, and a ∼ 10–30% ROM when NIFTP is considered malignant [18]. The 2017 Bethesda System recommends rFNA, molecular testing, or lobectomy for AUS/FLUS nodules [18].

Despite this update, there is heterogeneity in malignancy rates amongst Canadian centers and between centers in Canada and the United States [19–22]. Due to this lack of consensus, it is important to determine malignancy rates specific to populations of interest [19, 22, 23].

This study assesses the institution-specific malignancy rate and the effectiveness of rFNA for thyroid nodules with AUS/FLUS cytopathology at the Saint John Regional Hospital in Saint John, New Brunswick, the province's largest tertiary care centre with a catchment area serving a population of ∼ 170,000 [24, 25]. To the best of our knowledge this is the first study outlining AUS/FLUS thyroid cytopathology malignancy rate and treatment in New Brunswick, Canada. The results from our center add to the variable literature surrounding AUS/FLUS thyroid cytopathology and are discussed in relation to reported malignancy rates, specifically in a Canadian context.

Methods

Approval for retrospective data collection was obtained from the Horizon Health Network Research Ethics Board. All thyroid FNA results since the implementation of the Bethesda System in May 1, 2014–December 31, 2019 were screened, and all patients during this period who were ≥ 18 years old at the time of FNA and had AUS/FLUS thyroid cytopathology were included in the study.

Electronic health records were retrospectively reviewed. The patients’ biological sex, age at the time of first AUS/FLUS cytopathology result, treatment pathway, and pathology results were collected. A nodule was deemed malignant or benign based on surgical histopathology only. Histopathology was correlated to the nodule targeted by FNA by associating the location and size of the nodule. A sub-centimeter microcarcinoma not targeted by the FNA and not found within a larger nodule targeted by FNA was defined as incidental. The presence of an incidental microcarcinoma was noted but deemed benign for the purpose of this study. NIFTP/NEFV-PTC histopathology was considered malignant in this study as the inclusion period pre-dated the 2016 nomenclature and classification adjustment [17].

FNA cytopathology and surgical histopathology were reviewed by in-house pathologists. A specialist in Head and Neck pathology external to our institution was consulted in challenging cases. Final treatment decision making was in collaboration between the patient and the treating physicians. Unless more concerning features were present, AUS/FLUS surgical patients were referred for lobectomy, and if a thyroid carcinoma was identified, contralateral completion thyroidectomy was recommended.

Data analysis

The proportion of all thyroid FNAs which were classified as AUS/FLUS was calculated. The treatment pathway of the AUS/FLUS thyroid nodules and the distribution of rFNA results were described as percentages. If multiple rFNAs were performed for the same nodule, the most definitive rFNA result was reported. The malignancy rate was calculated for the nodules which underwent immediate resection and those which underwent resection after rFNA. Finally, the distribution of malignant histopathology was calculated.

The final malignancy rate was calculated as an upper limit estimate (ULE) and a lower limit estimate (LLE), as described by Ho et al. [23]. The ULE was the malignancy rate of the resected nodules. The LLE was calculated under the assumption that all the unresected nodules were benign, and therefore was a malignancy rate of all AUS/FLUS cytopathology results.

Results

During our inclusion period 1130 thyroid FNAs were performed at our center, of which 205 (18.1%) yielded AUS/FLUS cytopathology, 23 of which were rFNA results of previously categorized AUS/FLUS nodules and thus were not included as separate nodules. A total of 182 thyroid nodules with AUS/FLUS cytopathology from 177 patients were included in this study. The patients had a mean age of 58.5 +/− 15.5 years at the time of the AUS/FLUS cytopathology result. The majority of the patients (74.6%, or n = 132) were female. 25.4% (n = 45) were male.

The treatment pathway of the AUS/FLUS thyroid nodules is described in Fig. 1. Of the 182 nodules, 44 (24.2%) underwent rFNA, 79 (43.4%) underwent resection, and 59 (32.4%) were followed clinically and had no further pathology results available. 16/44 (36.4%) of the nodules which underwent rFNA were resected, and 7/16 (43.8%) of these were malignant. In contrast, 17/79 (21.5%) of the nodules which were resected without rFNA were malignant. The majority of AUS/FLUS surgical patients (84.4%) underwent initial lobectomy.

Fig. 1

Treatment pathway of the thyroid nodules with AUS/FLUS cytopathology at our center. Abbreviations: FNA – fine needle aspiration; AUS/FLUS – atypia of undetermined significance/follicular lesion of undetermined significance

In total 95/182 (52.2%) of the AUS/FLUS nodules were eventually resected, with 24/95 (25.3%) of these nodules yielding malignant histopathology, representing the ULE malignancy rate. 24/182 (13.2%), represents the LLE malignancy rate.

Table 1 represents the results of the 44 rFNAs, 45.5% were re-classified into more definitive categories, whereas 54.5% remained indeterminant (AUS/FLUS or non-diagnostic). The most common rFNA result was AUS/FLUS (36.4%) and the most common rFNA re-classification result was benign (25.0%).

Table 1

Results of the 44 rFNAs after initial AUS/FLUS cytopathology result

Classification	N = (%)	rFNA Result	Frequency (%)	Resected (%^a)	Malignant (%^b)
Indeterminant	24 (54.5%)	AUS/FLUS	16 (36.4%)	6 (37.5%)	2 (33.3%)
Indeterminant	24 (54.5%)	Non-Diagnostic	8 (18.2%)	2 (25.0%)	0 (0%)
Re-Classified	20 (45.5%)	Benign	11 (25.0%)	1 (9.1%)	0 (0%)
		FN/SFN	5 (11.4%)	3 (60.0%)	1 (33.3%)
		SFM	4 (9.1%)	4 (100.0%)	4 (100.0%)
		Malignant	0 (0%)	N/A	N/A

Abbreviations: AUS/FLUS atypia of undetermined significance/follicular lesion of undetermined significance, FN/SFN follicular neoplasm/suspicious for follicular neoplasm, SFM suspicious for malignancy

^aPercent of frequency

^bPercent of resected

Table 2 represents the histopathology reported from the 24 malignant outcomes. All were variants of papillary thyroid carcinoma (PTC). Three (12.5%) were sub-centimeter papillary thyroid microcarcinomas (PTMC) which were either targeted by the FNA or were found within a larger nodule which was targeted by the FNA. Incidental PTMCs were present in 14 (14.7%) of the resected specimens, 5 (5.3%) were found alongside macro-carcinomas in the indexed nodule, and 9 (9.5%) did not have a macro-carcinoma present and were categorized as benign (Table 3).

Table 2

Histopathology of 24 malignancies from thyroid nodules with AUS/FLUS cytopathology

Histopathology	Frequency (% of malignant)
FV-PTC	13 (54.2%)
Classic-PTC	4 (16.7%)
PTMC	3 (12.5%)
NIFTP	2 (8.3%)
TCV-PTC	1 (4.2%)
Oncocytic-PTC	1 (4.2%)

Abbreviations: FV-PTC follicular variant of papillary thyroid carcinoma, Classic-PTC classic or not specified variant of papillary thyroid carcinoma, PTMC papillary thyroid microcarcinoma, NIFTP non-invasive follicular thyroid neoplasms with papillary-like nuclear features, TCV-PTC tall cell variant of papillary thyroid carcinoma, Oncocytic-PTC oncocytic variant of papillary thyroid carcinoma

Table 3

Description of 14 incidental microcarcinomas

Histopathology	Frequency (% of resected)
With Macro-Carcinoma (Malignant)	5 (5.3%)
Without Macro-Carcinoma (Benign)	9 (9.5%)
Total	14 (14.7%)

Discussion

The Bethesda System for Reporting Thyroid Cytopathology effectively standardizes categorization of thyroid FNA results [12, 18]. However, the indeterminate nature of AUS/FLUS cytopathology has resulted in heterogeneous reports of malignancy rates for this category [13, 14]. The malignancy rate of AUS/FLUS thyroid cytopathology at our center is 13.2–25.3%.

Many centers report malignancy rates above the ∼ 5–15% ROM stated by the 2009 Bethesda System (Table 4) [11, 13, 14, 16, 19–23, 26–33]. The 2017 Bethesda System states a ∼ 10–30% ROM for AUS/FLUS thyroid cytopathology [18] which coincides well with our malignancy rate (13.2–25.3%). However, centers do report malignancy rates exceeding 30% (Table 4) [16, 19–21, 33].

Table 4

Malignancy rate of AUS/FLUS thyroid cytopathology reported at various centers

Series	Country	Period	AUS/FLUS Rate %	LLE Malignancy Rate %	ULE Malignancy Rate %
Present Study	Canada	2014–19	18.1 (205/1130)	13.2 (24/182)	25.3% (24/95)
The Bethesda System [11]	N/A	2009	≤7	∼ 5–15	N/A
The Bethesda System [18]	N/A	2017	≤10	∼ 10–30	N/A
Bernstein et al. [19]	Canada	2010–13	12.0	37 (86/233)	46 (86/187)
Erivwo & Ghosh [20]	Canada	2010–13	5.5	29.8 (54/181)	N/A
Oosthuizen et al. [21]	Canada	2010–16	N/A	N/A	32 (30/93)
Williams et al. [22]	Canada	2006–10	18.8	N/A	24.7 (N/A)
Wu et al. [15]	United States	2006–08	27.2	N/A	6 (3/51)
Hong et al. [16]	South Korea	2011–14	N/A	10.2 (70/687)	72.9 (70/96)
Ho et al. [23]	United States	2008–11	8.0	26.6 (144/541)	37.8 (144/381)
Cavalheiro et al. [26]	Brazil	2010–14	N/A	N/A	15.7 (75/478)
Mileva et al. [27]	Republic of Macedonia	2012–16	5.9	N/A	31.2 (35/112)^a
Al-Abbadi et al. [28]	Saudi-Arabia	2010–14	4.4	N/A	29 (12/42)^a
Wong et al. [29]	United States	2008–12	9	N/A	33.1 (60/181)
Yaprak Bayrak et al. [30]	Turkey	2012–17	4.2	N/A	25.0 (27/108)
Sullivan et al. [31]	United States	2003–12	6	17 (56/332)	33 (56/168)
Topaloglu et al. [32]	Turkey	N/A	N/A	N/A	23.4 (105/449)
Vanderlaan et al. [33]	United States	2005–09	10.9	29.0 (96/331)^a	48.2 (96/199)

Abbreviations: AUS/FLUS atypia of undetermined significance/follicular lesion of undetermined significance, LLE lower limit estimate, ULE upper limit estimate

^aIncludes malignant/benign diagnosis based on histopathology, core needle biopsy, or rFNA

In terms of Canadian data, the malignancy rate seems to vary geographically. The largest Canadian series of AUS/FLUS thyroid cytopathology was conducted in an Ontario center and yielded a 37–46% malignancy rate [19], which is noticeably higher than our center. A study in Newfoundland also reported a higher LLE malignancy rate of 29.8% [20]. However, centers in Western Canada [21] and Nova Scotia [22] reported ULE malignancy rates of 32 and 24.7% respectively, which are similar to our study. Overall, our malignancy rate is within the lower end of those reported in the literature (Table 4).

These higher malignancy rates may suggest the need for further adjustment of the ROM stated in the 2017 Bethesda System. However, it is also possible that there is no generalizable ROM for this cytopathology [34]. Rather, center and population specific factors may account for the variability of malignancy rates [19, 22, 23]. For example, Ho et al., [23] noted their higher malignancy rate (26.6–37.8%) may be attributed to their high volume cancer center setting, potentially resulting in a referral bias of more concerning nodules. Conversely, Cavalheiro et al. [26] reported a 15.7% malignancy rate from a center where all AUS/FLUS thyroid nodules were surgically resected and Wu et al. [15] reported a 6% malignancy rate for FNAs from community practice settings. As shown in these studies, there is a wide variability in the malignancy rate for this cytological diagnosis, and this illustrates the importance and value of identifying the malignancy rate at ones’ own institution.

Our center had a high rate of AUS/FLUS diagnosis (18.1%) compared to the Bethesda recommendation of ≤10% [18]. The common “overuse” of the category and the greater inter−/intra-observer variability of AUS/FLUS diagnosis has been noted [13]. The other Canadian center with a similar malignancy rate to this study also reported a high AUS/FLUS rate (18.8%) [22], whereas the two Canadian centers with higher malignancy rates had lower AUS/FLUS rates (5.5 and 12.0% respectively) [19, 20]. This relationship is observed in many studies cited in Table 4, and it is likely that lower AUS/FLUS rates correspond to higher malignancy rates. It has been hypothesized that higher AUS/FLUS rates (> 15%) result in more benign or non-diagnostic cases categorized as AUS/FLUS, whereas lower rates (< 5%) are associated with reduced sensitivity [13, 35], which is important knowledge for clinical decision making.

The Bethesda System recommends lobectomy, rFNA, or molecular testing for AUS/FLUS cytopathology [18]. At our center, the malignancy rate of nodules resected after rFNA (43.8%) was noticeably higher than those proceeding directly to surgery (21.5%). This can likely be attributed to nodules re-classified in more concerning categories (FN/SFN and SFM) representing 43.8% of the resections after rFNA. In contrast, the majority of nodules re-classified by rFNA yielded benign cytopathology (25.0%) and only one was resected. This is in line with previous studies [31, 36], and demonstrates the potential for rFNA to facilitate management of nodules originally classified as AUS/FLUS. However, varying rFNA re-classification rates are reported amongst Canadian centers [36, 37], suggesting value in determining the institutional rFNA re-classification rates.

This study has some limitations. Due to its retrospective nature, 52.2% of the thyroid nodules with AUS/FLUS cytopathology underwent surgical resection, while the remaining nodules lacked histopathology results and were not definitively classified as benign or malignant. They were assumed to be benign when calculating the LLE malignancy rate, however it is possible they contained an indolent, malignant neoplasm. Also, the number of rFNAs which underwent resection is small and a larger sample size would be required to provide stronger conclusions for this sub-group. Finally, this study considered NIFTP/NEFV-PTC histopathology as malignant due to the inclusion period pre-dating our institution's implementation of the 2016 nomenclature change [17]. A future study comparing the malignancy rate pre and post implementation of NIFTP nomenclature at our center would be of interest.

Conclusion

The malignancy rate of thyroid nodules with AUS/FLUS cytopathology at our center is 13.2–25.3%. Our malignancy rate is in line with the ROM stated by the Bethesda System (∼ 10–30%) [18]. Repeat FNA was helpful in re-classifying nearly 50% of the nodules that were biopsied and remains a useful technique in triaging these nodules. This study highlights the importance of establishing center-specific malignancy and rFNA re-classification rates to guide treatment decisions.

Footnotes

Acknowledgements

Not applicable.

Authors’ contributions

KH completed data collection and drafted the manuscript. TR, VM, and CJC designed the study, assisted in interpreting the results, and helped prepare and revise the manuscript. VN and AS facilitated data collection and helped revise the manuscript. All authors read and approved the final manuscript.

Funding

No funding was received for this study.

Availability of data and materials

The datasets used and analysed during the current study are available from the corresponding author upon reasonable request and approval from the Horizon Health Network Privacy Officer.

Declarations

Abbreviations

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

Dean

Epidemiology of thyroid nodules

Best Pract Res Clin Endocrinol Metab 2008 22 6 901 911 19041821 10.1016/j.beem.2008.09.019

Canadian Cancer Statistics Advisory Committee Canadian Cancer Statistics 2019 2019

Toronto

Canadian Cancer Society

cancer.ca/Canadian-Cancer-Statistics-2019-EN. Accessed 26 Oct 2019

Topstad

Dickinson

Thyroid cancer incidence in Canada: a national cancer registry analysis

CMAJ Open 2017 5 3 E612 E616 28807924 5621959 10.9778/cmajo.20160162

La Vecchia

Malvezzi

Bosetti

Garavello

Bertuccio

Levi

Thyroid cancer mortality and incidence: a global overview

Int J Cancer 2015 136 9 2187 2195 25284703 10.1002/ijc.29251

Vander

Gaston

Dawber

The significance of nontoxic thyroid nodules: final report of a 15-year study of the incidence of thyroid malignancy

Ann Intern Med 1968 69 537 540 1:STN:280:DyaF1czpvVOktg%3D%3D 5673172 10.7326/0003-4819-69-3-537

Woestyn

Afschrift

Schelstraete

Vermeulen

Demonstration of nodules in the normal thyroid by echography

Br J Radiol 1985 58 696 1179 1182 1:STN:280:DyaL2s%2Fnslalsw%3D%3D 3916164 10.1259/0007-1285-58-696-1179

Reiners

Wegscheider

Schicha

Theissen

Vaupel

Wrbitzky

Prevalence of thyroid disorders in the working population of Germany: ultrasonography screening in 96,278 unselected employees

Thyroid 2004 14 11 926 932 15671771 10.1089/thy.2004.14.926

Guth

Theune

Aberle

Galach

Bamberger

Very high prevalence of thyroid nodules detected by high frequency (13 MHz) ultrasound examination

Eur J Clin Investig 2009 39 8 699 706 1:STN:280:DC%2BD1MvosFCntw%3D%3D 10.1111/j.1365-2362.2009.02162.x

Hull

Critical analysis of two hundred twenty-one thyroid glands; study of thyroid glands obtained at necropsy in Colorado

AMA Arch Pathol 1955 59 3 291 311 1:STN:280:DyaG2M%2FltFSnsg%3D%3D 14349472

10.

Gharib

Goellner JR

Fine-needle aspiration biopsy of the thyroid: an appraisal

Ann Intern Med 1993 118 4 282 289 1:STN:280:DyaK3s7ivVOjtA%3D%3D 8420446 10.7326/0003-4819-118-4-199302150-00007

11.

Cibas

Ali

The Bethesda system for reporting thyroid cytopathology

Thyroid 2009 19 11 1159 1165 19888858 10.1089/thy.2009.0274

12.

Crowe

Linder

Omar

Salih

Roberson

Gidley

The impact of implementation of the Bethesda system for reporting cytopathology on the quality of reporting, “risk” of malignancy, surgical rate, and rate of frozen sections requested for thyroid lesions

Cancer Cytopathol 2011 119 5 315 321 21751427 10.1002/cncy.20174

13.

Kholová

Ludvíková

Thyroid atypia of undetermined significance or follicular lesion of undetermined significance: an indispensable Bethesda 2010 diagnostic category or waste garbage?

Acta Cytol 2014 58 4 319 329 25195864 10.1159/000366498

14.

Straccia

Rossi

Bizzarro

Brunelli

Cianfrini

Damiani

Fadda

A meta-analytic review of the Bethesda system for reporting thyroid cytopathology: has the rate of malignancy in indeterminate lesions been underestimated?

Cancer Cytopathol 2015 123 12 713 722 26355876 10.1002/cncy.21605

15.

Rose

Elsheikh

The Bethesda system for reporting thyroid cytopathology: an experience of 1,382 cases in a community practice setting with the implication for risk of neoplasm and risk of malignancy

Diagn Cytopathol 2012 40 5 399 403 21681976 10.1002/dc.21754

16.

Hong

Lee

Cho

Lee

Sung

Hong

Malignancy risk and related factors of atypia of undetermined significance/follicular lesion of undetermined significance in thyroid fine needle aspiration

Int J Endocrinol 2018 2018 4521984 1:CAS:528:DC%2BC1MXhslahsbjM 30154840 6091291 10.1155/2018/4521984

17.

Nikiforov

Seethala

Tallini

Baloch

Basolo

Thompson

LDR

Nomenclature revision for encapsulated follicular variant of papillary thyroid carcinoma: a paradigm shift to reduce overtreatment of indolent tumors

JAMA Oncol 2016 2 8 1023 1029 27078145 5539411 10.1001/jamaoncol.2016.0386

18.

Cibas

Ali

The 2017 Bethesda system for reporting thyroid cytopathology

Thyroid 2017 27 11 1341 1346 29091573 10.1089/thy.2017.0500

19.

Bernstein

Shah

MacMillan

Freeman

Institution-specific risk of papillary thyroid carcinoma in atypia/follicular lesion

Head Neck 2016 36 10 E1210 E1215 10.1002/hed.24193

20.

Erivwo

Ghosh

Atypia of undetermined significance in thyroid fine-needle aspirations: follow-up and outcome experience in Newfoundland

Canada Acta Cytol 2018 62 2 85 92 29486467 10.1159/000486779

21.

Oosthuizen

Walker

Todorovic

Masoudi

Wiseman

The presence of papillary features in thyroid nodules diagnosed as atypia of undetermined significance or follicular lesion of undetermined significance increases cancer risk and should influence treatment

Am J Surg 2018 215 5 819 823 29422426 10.1016/j.amjsurg.2017.12.018

22.

Williams

Bullock

Trites JR Taylor

Hart

Rates of thyroid malignancy by FNA diagnostic category

J Otolaryngol Head Neck Surg 2013 42 61 1 5

23.

Sarti

Jain

Wang

Nixon

Shaha

Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS)

Thyroid 2014 24 5 832 839 24341462 4948206 10.1089/thy.2013.0317

24.

Statistics Canada: Census Profile, 2016 Census. https://www12.statcan.gc.ca/census-recensement/2016/dp-pd/prof/details/page.cfm? Lang=E&Tab=1&Geo1=HR&Code1=1302&Geo2= PR&Code2=12&Data=Count&SearchText=Zone%202%20[Saint20John20area]&SearchType=Begins&SearchPR=01&B1=All&TABID=1. 2016. Accessed 15 Aug 2020.

25.

Horizon Health Network: Saint John Regional Hospital. https://en.horizonnb.ca/facilities-and-services/facilities/saint-john-regional-hospital.aspx (2020). Accessed 15 Aug 2020.

26.

Cavalheiro

Leite

AKN

de Matos

Miazaki

Ientile

Kulcsar

MAV

Malignancy rates in thyroid nodules classified as Bethesda categories III and IV: retrospective data from a tertiary center

Int J Endocrinol and Metab 2018 16 1 e12871

27.

Mileva

Stoilovska

Jovanovska

Ugrinska

Petrushevska

Kostadinova-Kunovska

Thyroid cancer detection rate and associated risk factors in patients with thyroid nodules classified as Bethesda category III

Radiol Oncol 2018 52 4 370 376 30265655 6287180 10.2478/raon-2018-0039

28.

Al-Abbadi

Shareef

Yousef

Almasri

Mustafa

Aljawad

A follow-up study on thyroid aspirates reported as atypia of undetermined significance/follicular lesion of undetermined significance and follicular neoplasm/suspicious for follicular neoplasm: a multicenter study from the Arabian gulf region

Diagn Cytopathol 2017 45 11 983 988 28862810 10.1002/dc.23805

29.

Wong

LiVolsi

Baloch

Diagnosis of atypia/follicular lesion of undetermined significance: an institutional experience

Cytojournal 2014 11 23 25210530 4158655 10.4103/1742-6413.139725

30.

Yaprak Bayrak

Eruyar

Malignancy rates for Bethesda III and IV thyroid nodules: a retrospective study of the correlation between fine-needle aspiration cytology and histopathology

BMC Endocr Disord 2020 20 1 1 9 10.1186/s12902-020-0530-9

31.

Sullivan

Hirschowitz

Fung

Apple

The impact of atypia/follicular lesion of undetermined significance and repeat fine-needle aspiration: 5 years before and after implementation of the Bethesda system

Cancer Cytopathol 2014 122 12 866 872 25078420 10.1002/cncy.21468

32.

Topaloglu

Baser

Cuhaci

Sungu

Yalcin

Ersoy

Malignancy is associated with microcalcification and higher AP/T ratio in ultrasonography, but not with Hashimoto's thyroiditis in histopathology in patients with thyroid nodules evaluated as Bethesda category III (AUS/FLUS) in cytology

Endocrine 2016 54 1 156 168 1:CAS:528:DC%2BC28XnslKrsL4%3D 27172917 10.1007/s12020-016-0982-x

33.

VanderLaan

Marqusee

Krane

Usefulness of diagnostic qualifiers for thyroid fine-needle aspirations with atypia of undetermined significance

Am J Clin Pathol 2011 136 4 572 577 21917679 10.1309/AJCPO0BQ2YSKPXXP

34.

Heller

Malignancy rate in thyroid nodules classified as Bethesda category III (AUS/FLUS): is there a correct answer?

Thyroid 2014 24 5 787 788 24684214 10.1089/thy.2014.0142

35.

Renshaw

Subclassification of atypical cells of undetermined significance in direct smears of fine-needle aspirations of the thyroid: distinct patterns and associated risk of malignancy

Cancer Cytopathol 2011 119 5 322 327 21442771 10.1002/cncy.20154

36.

Allen

Al Afif

Rigby

Bullock

Trites

Taylor

The role of repeat fine needle aspiration in managing indeterminate thyroid nodules

J Otolaryngol Head Neck Surg 2019 48 1 1 5 10.1186/s40463-019-0338-7

37.

Jooya

Saliba

Blackburn

Tamilia

Hier

Mlynarek

The role of repeat fine needle aspiration in the management of indeterminate thyroid nodules

J Otolaryngol Head Neck Surg 2016 45 1 1 6 10.1186/s40463-016-0164-0

Rate of malignancy for thyroid nodules with AUS/FLUS cytopathology in a tertiary care center – a retrospective cohort study

Abstract

Background

Methods

Results

Conclusion

Keywords

Background

Methods

Data analysis

Results

Discussion

Conclusion

Footnotes

Acknowledgements

Authors’ contributions

Funding

Availability of data and materials

Declarations

Abbreviations

References